Generic Drugmakers Struggle Despite U.S. Push for Copycats
- Mylan, Perrigo, squeezed by pricing pressure, ponder overhauls
- Launching higher-priced alternatives has proven challenging
This article is for subscribers only.
Generic drugmakers are being crushed by the very forces that the Trump administration is counting on to drive down prescription costs.
While policy makers are betting that opening the market to a deluge of new medicines and reforming the drug supply chain will help contain rising prices, many widely used copycat medications are already seeing their prices fall at such a rapid rate that their makers are struggling to keep their heads above water.